Advertisement

Using a Modified Yeast Two-Hybrid System to Screen for Chemical GEF Inhibitors

  • Anne Blangy
  • Philippe FortEmail author
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 928)

Abstract

GTPases of the Ras superfamily act as signaling switches, active when bound to GTP and inactive when bound to GDP. There is now considerable evidence that over-activation of Ras-like pathways participates in the development of many cancer types. In particular, GTPases of the Rho family control cell adhesion, survival, motility, and invasion, cell properties dysregulated in most cancer types. Rho activation is triggered by RhoGEFs, most of which form complexes with growth-factor receptors and initiate downstream Rho signaling pathways in response to extracellular clues. As such, RhoGEFs represent attractive targets to inhibit Rho pathways and may have interesting druggability for cancer therapeutics. Here we describe a procedure derived from the yeast two-hybrid system, in which activation of a mammalian Rho GTPase by its cognate RhoGEF is converted into variation in the yeast growth. The experimental design is thus suitable for identiying RhoGEF inhibitors and has been optimized for medium-throughput screening. The major advantages of this method lie in the direct monitoring of GEF activity in a living organism and the rapid detection of false positive hits.

Key words

Rho signaling RhoGEF Two-hybrid Screening Chemicals 

Notes

Acknowledgments

We are indebted to Pauline Larrousse for technical support. This work was funded by institutional grants from CNRS and Montpellier universities, and by contracts from ANR (ANR-06-PCVI-0024), ARC (n° 1048), FRM (DVO20081013473), and Arthritis Fondation Courtin (OPT30713).

References

  1. 1.
    Shirai H, Autieri M, Eguchi S (2007) Small GTP-binding proteins and mitogen-activated protein kinases as promising therapeutic targets of vascular remodeling. Curr Opin Nephrol Hypertens 16:111–5PubMedCrossRefGoogle Scholar
  2. 2.
    Fritz G, Just I, Kaina B (1999) Rho GTPases are over-expressed in human tumors. Int J Cancer 81:682–7PubMedCrossRefGoogle Scholar
  3. 3.
    Bosco EE, Mulloy JC, Zheng Y (2009) Rac1 GTPase: a “Rac” of all trades. Cell Mol Life Sci 66:370–4PubMedCrossRefGoogle Scholar
  4. 4.
    Boureux A, Vignal E, Faure S, Fort P (2007) Evolution of the Rho family of ras-like GTPases in eukaryotes. Mol Biol Evol 24:203–16PubMedCrossRefGoogle Scholar
  5. 5.
    Rossman KL, Der CJ, Sondek J (2005) GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors. Nat Rev Mol Cell Biol 6:167–80PubMedCrossRefGoogle Scholar
  6. 6.
    Meller N, Merlot S, Guda C (2005) CZH proteins: a new family of Rho-GEFs. J Cell Sci 118:4937–46PubMedCrossRefGoogle Scholar
  7. 7.
    Diaz-Flores E, Shannon K (2007) Targeting oncogenic Ras. Genes Dev 21:1989–92PubMedCrossRefGoogle Scholar
  8. 8.
    Vega FM, Ridley AJ (2008) Rho GTPases in cancer cell biology. FEBS Lett 582:2093–101PubMedCrossRefGoogle Scholar
  9. 9.
    Lazer G, Katzav S (2010) Guanine nucleotide exchange factors for RhoGTPases: Good therapeutic targets for cancer therapy? Cell Signal 23:969–79PubMedCrossRefGoogle Scholar
  10. 10.
    Leonard DA, Evans T, Hart M, Cerione RA, Manor D (1994) Investigation of the GTP-binding/GTPase cycle of Cdc42Hs using fluorescence spectroscopy. Biochemistry 33:12323–8PubMedCrossRefGoogle Scholar
  11. 11.
    Sander EE, van Delft S, ten Klooster JP, Reid T, van der Kammen RA, Michiels F, Collard JG (1998) Matrix-dependent Tiam1/Rac signaling in epithelial cells promotes either cell-cell adhesion or cell migration and is regulated by phosphatidylinositol 3-kinase. J Cell Biol 143:1385–98PubMedCrossRefGoogle Scholar
  12. 12.
    Zheng Y, Hart MJ, Cerione RA (1995) Guanine nucleotide exchange catalyzed by dbl oncogene product. Methods Enzymol 256:77–84PubMedCrossRefGoogle Scholar
  13. 13.
    De Toledo M, Colombo K, Nagase T, Ohara O, Fort P, Blangy A (2000) The yeast exchange assay, a new complementary method to screen for Dbl-like protein specificity: identification of a novel RhoA exchange factor. FEBS Lett 480:287–92PubMedCrossRefGoogle Scholar
  14. 14.
    Blangy A, Bouquier N, Gauthier-Rouviere C, Schmidt S, Debant A, Leonetti JP, Fort P (2006) Identification of TRIO-GEFD1 chemical inhibitors using the yeast exchange assay. Biol Cell 98:511–22PubMedCrossRefGoogle Scholar
  15. 15.
    Bouquier N, Vignal E, Charrasse S, Weill M, Schmidt S, Leonetti JP, Blangy A, Fort P (2009) A cell active chemical GEF inhibitor selectively targets the Trio/RhoG/Rac1 signaling pathway. Chem Biol 16:657–66PubMedCrossRefGoogle Scholar
  16. 16.
    Vives V, Laurin M, Cres G, Larrousse P, Morichaud Z, Noel D, Cote JF, Blangy A (2011) The Rac1 exchange factor Dock5 is essential for bone resorption by osteoclasts. J Bone Miner Res 26(5):1099–110PubMedCrossRefGoogle Scholar
  17. 17.
    Vignal E, Blangy A, Martin M, Gauthier-Rouviere C, Fort P (2001) Kinectin is a key effector of RhoG microtubule-dependent cellular activity. Mol Cell Biol 21:8022–34PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  1. 1.Universités Montpellier2 & 1MontpellierFrance
  2. 2.Universités Montpellier2 & 1, CRBMMontpellierFrance
  3. 3.CNRS, UMR5237MontpellierFrance

Personalised recommendations